TC
MRSN

TwinBeech Capital’s Mersana Therapeutics MRSN Stock Holding History

TwinBeech Capital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-863
Closed -$293K – 700
2021
Q2 		$293K Buy
+863
New +$327K 0.04% 376

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TwinBeech Capital's MRSN Position: Q3 2021 in Review

TwinBeech Capital sold out of Mersana Therapeutics (MRSN) in Q3 2021, closing a stake of 863 shares — an estimated $293K sold.

TwinBeech Capital first reported a position in MRSN in Q2 2021 and held it in 1 quarter. The position peaked at $293K in Q2 2021. 109 funds tracked by Wall St. Rank hold MRSN as of Q3 2021.

  • TwinBeech Capital reported no remaining Mersana Therapeutics position as of Q3 2021 after selling out during the quarter.
  • TwinBeech Capital sold 863 Mersana Therapeutics shares in Q3 2021, an estimated $293K.
  • TwinBeech Capital first reported a position in Mersana Therapeutics in Q2 2021 and held it in 1 quarter.
  • TwinBeech Capital's Mersana Therapeutics position peaked at $293K in Q2 2021.
  • 109 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2021.

Based on TwinBeech Capital's 13F filing for Q3 2021, filed 15 Nov 2021.